phrykt

Lineage Cell Therapeutics, Inc. (LCTX): who owns it and who trades it

As of Nov 16, 2026, LCTX insiders reported 2 purchases worth $41.5K in the last 12 months. The largest buyer was Brian M Culley (CEO), with $24.4K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Lineage Cell Therapeutics

From the latest filings

Overall: about as much buying as selling. Famous investors mostly sold. Insiders mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns LCTX

131 funds and institutions reported LCTX shares worth $153M at the end of Q2 2026, about 47% of the company. The largest holder is Broadwood Capital Inc with 19.9%.

Funds and institutions (13F) 47%Everyone else 53%

10 largest owners, by share of the company

Broadwood Capital Inc19.9%
BlackRock, Inc.5.3%
Vanguard Capital Management LLC3.6%
Defender Capital, LLC.2.6%
Geode Capital Management, LLC2.1%
Raffles Associates LP2.1%
Fifth Third Bancorp1.8%
Millennium Management LLC1.2%
State Street Corp0.9%
Vanguard Fiduciary Trust Co0.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Broadwood Capital Inc49.56M19.90%$64.9MNo change
BlackRock, Inc.13.19M5.29%$17.3M+241%
Vanguard Capital Management LLC9.05M3.64%$11.9M+9%
Defender Capital, LLC.6.60M2.65%$8.6M-2%
Geode Capital Management, LLC5.30M2.13%$6.9M+110%
Raffles Associates LP5.20M2.09%$6.8M-3%
Fifth Third Bancorp4.60M1.85%$6MNo change
Millennium Management LLC3.02M1.21%$4M-46%
State Street Corp2.31M0.93%$3M+112%
Vanguard Fiduciary Trust Co1.67M0.67%$2.2M+26%
Northern Trust Corp1.66M0.67%$2.2M+232%
Morgan Stanley1.47M0.59%$1.9M-21%
Renaissance Technologies LLC1.34M0.54%$1.8M-37%
Marshall Wace, LLP1.28M0.51%$1.7M-58%
Vanguard Portfolio Management LLC1.27M0.51%$1.7M–
UBS Group AG687,0510.28%$900K-50%
Red Crane Wealth Management, LLC597,2630.24%$782KNo change
Charles Schwab Investment Management Inc577,4350.23%$756K+344%
Sixth Street Partners Management Company, L.P.577,4350.23%$756K–
Barclays PLC508,6680.20%$666K+29%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, LCTX insiders reported $41.5K of open-market purchases and $0 of sales.

Purchases, 12 months
$41.5K
2 trades, 2 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Nov 16, 2026
Filed Nov 16, 2026

Purchases and sales by month

$24.4K$24.4KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 16, 2026Jill Ann HoweCFOPurchase20,000$0.85$17.1KForm 4
Mar 12, 2026Brian M CulleyCEOPurchase15,000$1.63$24.4KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Brian M CulleyPresident and CEO, Director$24.4K–Mar 12, 2026
Jill Ann HoweChief Financial Officer$17.1K–Nov 16, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

LCTX short interest

Moderate short interest. 9.6% of LCTX shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went down 6%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 24.35M LCTX shares were sold short, 9.6% of the shares outstanding, down 6.1% from the report before. At the average daily volume of 1.26M shares, buying them all back would take about 19.3 trading days (days to cover).

Shares short, % of all shares

9.63%May 15Oct 3012.3%

Days to cover

19.3May 15Oct 3039.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202624.35M9.63%-6%1.26M19.3
Oct 15, 202625.93M10.25%-11%1.55M16.8
Sep 30, 202629.09M11.50%-1%1.85M15.8
Sep 15, 202629.47M11.65%+2%1.11M26.6
Aug 31, 202628.98M11.46%+2%876,20533.1
Aug 14, 202628.33M11.20%-4%808,10935.1
Jul 31, 202629.56M11.87%-1%1.13M26.2
Jul 15, 202629.87M11.99%+6%862,08734.6
Jun 30, 202628.19M11.32%+10%3.38M8.3
Jun 15, 202625.56M10.26%-2%1.11M23.0
May 29, 202626.08M10.47%+1%1.05M25.0
May 15, 202625.92M10.40%+1%1.55M16.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Lineage Cell Therapeutics company events

Lineage Cell Therapeutics filed 7 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Aug 6, 2026.

  1. Aug 6, 2026ResultsReleased financial results. Filing
  2. Jun 12, 2026AnnouncementAs previously reported, in January 2026, the Company applied for a Clinical Trial (CLIN2) award from the California Institute for Regenerative Medicine to support continued clinical development of OPC1 for the treatment of spinal cord injuries. Filing
  3. May 12, 2026ResultsReleased financial results. Filing
  4. Mar 11, 2026AnnouncementLineage Cell Therapeutics, Inc. filed with the U.S. Securities and Exchange Commission a prospectus supplement dated March 11, 2026 to the prospectus dated May 14, 2024 that forms a part of the Company’s shelf registration statement on Form S-3 (File No. 333-277758) filed by the Company with the… Filing
  5. Mar 5, 2026ResultsReleased financial results. Filing
  6. Nov 28, 2025AnnouncementAs previously reported, Lineage Cell Therapeutics, Inc. applied for a Clinical Trial (CLIN2) award from the California Institute for Regenerative Medicine in June 2025 to support continued clinical development of OPC1 for the treatment of spinal cord injuries. Filing
  7. Nov 24, 2025AnnouncementAs previously reported, in December 2021, Lineage Cell Therapeutics, Inc., entered into a collaboration and license agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. under which our lead cell therapy program known as OpRegen® (also known as RG6501) is being developed for the treatment of… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Lineage Cell Therapeutics financials

Famous investors that hold LCTX

4 of the 50 well-known investors we track reported holding LCTX in their latest 13F filing. The largest position is Israel Englander's, worth $2.5M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20262.63M$2.5M0.0%-13%
Jim Simons · Renaissance TechnologiesQ3 2026674,529$645K0.0%-50%
Ken Griffin · Citadel AdvisorsQ3 2026341,881$327K0.0%-20%
Steve Cohen · Point72 Asset ManagementQ3 202629,128$27.8K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Lineage Cell Therapeutics, Inc. (LCTX) stock

Who owns the most LCTX stock?

The largest reported owner of Lineage Cell Therapeutics, Inc. (LCTX) is Broadwood Capital Inc, with 19.9% of the company. In total, 131 funds and institutions reported holding LCTX at the end of Q2 2026, together about 47% of the shares. See the largest owners.

Are LCTX insiders buying or selling?

In the last 12 months, LCTX insiders reported 2 open-market purchases worth $41.5K and no sales. The latest trade was on Nov 16, 2026. See every trade.

What is the short interest in LCTX?

As of Oct 30, 2026, 24.35M LCTX shares were sold short, 9.6% of the shares outstanding, down 6.1% from the report before. At the average daily volume of 1.26M shares, buying them all back would take about 19.3 trading days (days to cover). See the history.

Which famous investors hold LCTX?

4 of the 50 well-known investors we track reported LCTX in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $2.5M. See all holders.

Executive pay

Lineage Cell Therapeutics's chief executive was paid a total of $2.1M for the year ended Dec 31, 2025, down 17% from $2.5M the year before. In the last 12 months, Lineage Cell Therapeutics's executives and directors bought $41.5K of stock on the open market and sold none.

Chief executive, total pay$2.1MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$6.3MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$992KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.